Barclays downgrades Haleon to ‘equalweight’, says question marks over US persist
Barclays downgraded GSK’s consumer health spinoff Haleon on Tuesday to ‘equalweight’ from ‘overweight’ as it said questions marks persist over the US and there are "a few new clouds on the horizon".
Haleon
16 September 2025 09:38:35
Source: Sharecast
The bank noted that the US accounts for 34% of sales and said it is seeing slower category growth and destocking.
"Haleon is overweight declining US drug stores," it said, adding that the US was the reason Haleon lowered its 2025 organic sales growth guidance to around 3.5%. Barclays said it still sees short-term risks.
"Haleon has a new US head but we move to the sidelines as we await the plan," it said.
At 0915 BST, the shares were down 2.8% at 346.78p.
Scottish Widows is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
